KORU Medical Systems

KRMD

Market cap $270M

MAHWAH, N.J.--(BUSINESS WIRE)--KORU Medical Systems, Inc. (NASDAQ: KRMD) (“KORU Medical” or the “Company”), a leading medical technology company focused on innovative and patient-centric large volume subcutaneous infusion solutions, today announced that the Company will present its latest research at the ESID/EHA/SIOPE Focused Symposium 2025 in Vienna, Austria, November 18-20. The poster presentation, titled “Comparing Mechanical Pump and Manual Push for Short-Duration Subcutaneous Infusions: A.

MAHWAH, N.J.--(BUSINESS WIRE)--KORU Medical Systems (NASDAQ: KRMD) (“KORU Medical” or the “Company”), a leading medical technology company focused on the development, manufacturing, and commercialization of innovative and patient-centric large volume subcutaneous infusion solutions, today announced that the Company will be participating in three upcoming Investor Conferences. KORU Medical's management team is participating at the 16th Annual Craig-Hallum Alpha Select Conference on Tuesday, Nove.

KORU Medical Systems, Inc. ( KRMD ) Q3 2025 Earnings Call November 12, 2025 4:30 PM EST Company Participants Linda Tharby - President, CEO & Director Tom Adams - CFO, Secretary & Treasurer Conference Call Participants Louisa Smith - Gilmartin Group LLC Frank Takkinen - Lake Street Capital Markets, LLC, Research Division Caitlin Cronin - Canaccord Genuity Corp., Research Division Joseph Downing - Piper Sandler & Co., Research Division Chase Knickerbocker - Craig-Hallum Capital Group LLC, Research Division Presentation Operator Greetings, and welcome to KORU Medical Systems Third Quarter 2025 Earnings Conference Call. [Operator Instructions] Please note, this conference is being recorded.

KORU Medical Systems, Inc. (KRMD) came out with a quarterly loss of $0.02 per share versus the Zacks Consensus Estimate of a loss of $0.03. This compares to a loss of $0.03 per share a year ago.

MAHWAH, N.J.--(BUSINESS WIRE)--KORU Medical Systems, Inc. (NASDAQ: KRMD) (“KORU Medical” or the “Company”), a leading medical technology company focused on development, manufacturing, and commercialization of innovative and patient-centric large volume subcutaneous infusion solutions, today reported financial results for the third quarter ended September 30, 2025. Recent Highlights • Third quarter 2025 net revenues of $10.4 million, a 27% increase over the prior year period • Core business (Dom.

MAHWAH, N.J.--(BUSINESS WIRE)--KORU Medical Systems, Inc. (NASDAQ: KRMD) (“KORU Medical” or the “Company”), a leading medical technology company focused on the development, manufacturing, and commercialization of innovative and easy-to-use patient-centric large volume subcutaneous infusion solutions, today announced a development agreement with a global pharmaceutical company. The agreement allows for broad collaboration on next-generation infusion systems in subcutaneous immunoglobulin (SCIg).

MAHWAH, N.J.--(BUSINESS WIRE)--KORU Medical Systems, Inc. (NASDAQ: KRMD) (“KORU Medical” or the “Company”), a leading medical technology company focused on development, manufacturing, and commercialization of innovative and patient-centric large volume subcutaneous infusion solutions, today announced that the Company will report third quarter 2025 financial results on Wednesday, November 12, 2025. KORU Medical's management will host a conference call and webcast at 4:30 p.m. ET that day to disc.

DENVER & MAHWAH, N.J.--(BUSINESS WIRE)--ForCast Orthopedics, Inc. and KORU Medical Systems, Inc. (NASDAQ: KRMD) today jointly announced an agreement leveraging KORU Medical's FreedomEDGE® infusion system as part of ForCast's technology platform for the treatment of periprosthetic joint infection (PJI). PJI is a rare but serious complication of joint replacement procedures, and is challenging to treat because the infecting bacteria adhere to the prothesis and can form a protective biofilm which.

Does KORU Medical Systems, Inc. (KRMD) have what it takes to be a top stock pick for momentum investors? Let's find out.

BROOKLYN PARK, Minn., Aug. 28, 2025 (GLOBE NEWSWIRE) -- Cirtec Medical, a leading strategic outsourcing partner for complex minimally invasive, active implantable devices and precision components, is pleased to announce the appointment of Shar Matin as Chief Executive Officer, effective September 2, 2025.